Form 4: Director Gary Patou Sells Xenon Pharmaceuticals Shares

Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals to cover tax obligations related to RSU vesting.

Summary

• Director Gary Patou sold 1,322 common shares of Xenon Pharmaceuticals Inc. (XENE) on June 5, 2026.
• The shares were sold at a price of $53.14 per share.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 17, 2025.
• Following the transaction, the reporting person holds 24,896 shares directly and 4,902 shares indirectly via a family trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was a pre-planned administrative action to satisfy tax liabilities.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, indicating the transaction was not based on non-public information.

Negatives

• Insider selling, even if pre-planned, reduces the direct equity stake held by a member of the board.

Risks

• None identified beyond standard market risks associated with pharmaceutical equity holdings.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling to cover tax obligations from RSU vesting is a standard corporate governance practice and typically does not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives and directors to manage equity holdings while avoiding potential conflicts with insider trading regulations.

Related Party Transactions

• The reporting person maintains indirect ownership of 4,902 shares through the Gary & Karen Barbara Patou TTEE Patou Family Trust.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and relatively small in volume.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Insider Trading, Form 4, Biotech, Director Sale